12/23
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
12/20
08:16 am
svra
Savara Inc (NASDAQ: SVRA) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $8.00 price target on the stock.
Low
Report
Savara Inc (NASDAQ: SVRA) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $8.00 price target on the stock.
12/19
10:24 am
svra
Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
Low
Report
Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
12/18
04:17 pm
svra
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
Medium
Report
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
12/18
04:05 pm
svra
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Medium
Report
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
12/17
04:05 pm
svra
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
11/25
09:40 am
svra
Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA) [Yahoo! Finance]
Low
Report
Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA) [Yahoo! Finance]
11/22
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
11/22
08:11 am
svra
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 [Yahoo
Medium
Report
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 [Yahoo
11/22
08:05 am
svra
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Medium
Report
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
11/13
10:08 am
svra
Savara Inc (NASDAQ: SVRA) had its price target lowered by analysts at HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
Savara Inc (NASDAQ: SVRA) had its price target lowered by analysts at HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.
11/13
08:20 am
svra
Savara Announces Participation in Upcoming Healthcare Conferences [Yahoo! Finance]
High
Report
Savara Announces Participation in Upcoming Healthcare Conferences [Yahoo! Finance]
11/13
08:05 am
svra
Savara Inc (NASDAQ: SVRA) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $5.00 price target on the stock, down previously from $7.00.
High
Report
Savara Inc (NASDAQ: SVRA) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $5.00 price target on the stock, down previously from $7.00.
11/13
08:05 am
svra
Savara Announces Participation in Upcoming Healthcare Conferences
High
Report
Savara Announces Participation in Upcoming Healthcare Conferences
11/12
08:05 am
svra
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
11/4
04:24 pm
svra
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference [Yahoo! Finance]
Low
Report
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference [Yahoo! Finance]
11/4
04:05 pm
svra
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Low
Report
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
10/22
08:05 am
svra
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
Medium
Report
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
10/18
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
10/8
08:45 am
svra
Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.